SynthesisThoracic cancer2026
Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.
Synthesis in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor administered before chemotherapy, reduces chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but its efficacy across solid tumors remains unclear. This meta-analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) and cohort studies comparing chemotherapy with or without trilaciclib were included. Primary outcomes were severe neutropenia (SN), febrile neutropenia (FN), duration of severe neutropenia (DSN), Grade 3/4 leukopenia, and granulocyte colony-stimulating factor (G-CSF) use. Secondary outcomes included other hematologic toxicities, supportive care interventions, and efficacy outcomes. Ten studies involving 1172 patients (six RCTs and four cohort studies) were identified. Trilaciclib significantly reduced SN (OR, 0.14; 95% CI, 0.06-0.31; p < 0.001), FN (OR, 0.19; 95% CI, 0.11-0.36; p < 0.001), Grade 3/4 leukopenia (OR, 0.25; 95% CI, 0.13-0.46; p < 0.001), and G-CSF use (OR, 0.36; 95% CI, 0.18-0.71; p = 0.0087), and shortened DSN (MD, -2.30 days; 95% CI, -4.28 to -0.31; p = 0.0309). It also reduced Grade 3/4 anemia and thrombocytopenia and decreased use of erythropoiesis-stimulating agents, red blood cell transfusions, and platelet transfusions. Overall survival showed a borderline improvement (HR, 0.84; 95% CI, 0.71-0.99; p = 0.0373), while no significant differences were observed in progression-free survival, overall response rate, or non-hematologic adverse events. Subgroup analyses suggested greater benefit in ES-SCLC. Overall, trilaciclib before chemotherapy significantly reduced CIM and supportive care needs, with no apparent compromise in antitumor efficacy and more pronounced effects in ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.